Commercial-Scale Biologics / mAb CDMOs

· updated as new inspection, certificate, and trial data enters the platform

Biologics / mAb manufacturers on CDMO Signal: 20 listed, 20 with a Signal Score. Together they have 49 FDA inspections on file (including 23 NAI, 26 VAI and 0 OAI) and 145 EMA/MHRA GMP certificates. Fewer than three are fully evidenced (all four score pillars and at least one ClinicalTrials.gov match), so this page does not name a top three. The score does not measure expression host, validated bioreactor scale, or whether fill-finish is on the same site. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology. This page is the commercial-scale filter: a high Signal Score or a broad ClinicalTrials.gov footprint. It is not a list of approved commercial products.

20
CDMOs tracked
20
Fully scored
15
With FDA records
49
FDA inspections
145
EMA/MHRA GMP certs

Biologics CDMOs manufacture monoclonal antibodies, fusion proteins, and other large molecules in mammalian (typically CHO) cell culture. It is the largest and most mature segment of contract manufacturing, spanning early clinical supply through multi-thousand-litre commercial production.

Selecting a biologics CDMO turns on bioreactor scale and modality fit (mAb, bispecific, fusion protein), titer and cell-line strategy, fill-finish, and — above all — a clean regulatory record at commercial scale. The rankings below score each CDMO on FDA inspection history, EMA/MHRA GMP certification, clinical-program activity, and capacity.

FDA inspection outcomes across these CDMOs: 23 NAI (no action), 26 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (31), Denmark (29), UNITED KINGDOM (29), Germany (21), Italy (16).

Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing contract manufacturers only.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
PC
Kalamazoo, MI · McPherson, KS
Fully evidenced
Also makes its own products
90.1 100.0 4 insp · 14 GMP 2025-12-16 · NAI — 366 programs
2
PR
Lexington, KY · Riverview, MI · Ahmedabad, IN
86.9 96.0 7 insp · 15 GMP 2026-02-13 · VAI — —
3
FD
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Hiring · 20 open roles
86.7 100.0 0 insp · 35 GMP None on file Expanding —
4
AJ
San Diego, CA · Osaka, JP
83.5 100.0 0 insp · 1 GMP None on file — —
5
CD
Plankstadt, DE · Caponago, IT · Boulder, CO
83.1 99.3 5 insp · 17 GMP 2025-11-14 · NAI — —
6
RB
Hamburg, Germany
82.9 100.0 0 insp · 9 GMP None on file — —
7
MK
Darmstadt, DE · St. Louis, MO
Hiring · 8 open roles
Fully evidenced
Also makes its own products
81.9 98.8 2 insp · 2 GMP 2025-04-28 · VAI — 22 programs
8
LB
Incheon, KR · Syracuse, NY
Hiring · 8 open roles
81.6 100.0 2 insp · 0 GMP 2026-09-18 · NAI — —
9
EF
Planegg, DE · San Diego, CA
81.6 100.0 7 insp · 0 GMP 2026-05-15 · NAI — —
10
EK
Birmingham, AL · Vancouver, BC
81.5 99.8 2 insp · 2 GMP 2025-09-11 · NAI — —
11
NW
Vilnius, LT; Waltham (MA), USA
Hiring · 16 open roles
80.8 100.0 0 insp · 8 GMP None on file Available —
12
SG
Bengaluru, India
Hiring · 4 open roles
80.3 100.0 3 insp · 0 GMP 2025-02-20 · NAI — —
13
BR
Glasgow, UK · Rockville, MD
Hiring · 16 open roles
Also makes its own products
80.3 97.2 6 insp · 10 GMP 2026-05-13 · VAI — —
14
CRA
Albany, NY · Albuquerque, NM
Hiring · 48 open roles
79.5 100.0 2 insp · 18 GMP 2025-12-02 · NAI — —
15
AV
Tustin, CA
Hiring · 36 open roles
78.9 100.0 1 insp · 0 GMP 2025-05-29 · NAI — —
16
Oklahoma City, OK
78.6 98.2 1 insp · 0 GMP 2026-06-17 · VAI Available —
17
PG
Berlin, DE
78.1 100.0 0 insp · 4 GMP None on file — —
18
BT
Charlottetown, PE, Canada
76.5 99.4 1 insp · 0 GMP 2022-08-26 · VAI — —
19
KD
Woodbury, MN
76.1 98.5 3 insp · 9 GMP 2025-11-13 · VAI — —
20
AF
Charlottesville, VA
Hiring · 9 open roles
75.2 96.5 3 insp · 1 GMP 2024-05-08 · VAI — —
How we score CDMOs →

What to evaluate in a Biologics / mAb CDMO

Scale & bioreactor fit
Match validated bioreactor scale (from a few hundred litres clinical to 2,000L+ commercial) and single-use vs stainless to your dose and indication. Confirm titer expectations for your construct.
Cell line & process development
Ask whether the CDMO offers its own expression platform/cell line or works from yours, and how process development and tech transfer are handled.
Regulatory track record
Biologics programs heading to BLA/MAA need a strong commercial-scale inspection history. Cross-check FDA 483s, warning letters, and EMA/MHRA GMP coverage — all shown above.
Drug substance to drug product
Confirm whether the CDMO covers fill-finish and formulation in-house or coordinates a separate site, which affects timelines and comparability.

Biologics / mAb CDMOs — Frequently Asked Questions

How many Biologics / mAb CDMOs have FDA inspection records?
CDMO Signal tracks 15 Biologics / mAb CDMOs with FDA inspection records and 145 EMA/MHRA GMP certificates across the group.
What should I look for in a biologics CDMO?
Match bioreactor scale and modality (mAb, bispecific, fusion protein) to your program, confirm cell-line and process-development support, and prioritize a clean FDA and EMA/MHRA record at the scale you'll commercialize at.
What is the difference between a biologics CDMO and a cell or gene therapy CDMO?
Biologics CDMOs make large molecules (antibodies, proteins) in bioreactors at litre-to-thousands-of-litre scale. Cell and gene therapy CDMOs make living cells or viral vectors in much smaller, often per-patient batches under different containment and analytics.
Related modalities
Recombinant Proteins CDMOs mRNA / LNP CDMOs Cell Therapy CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy Viral Vector